Bisphosphonate therapy

ApprovedSmall molecule

SState University of New York - Upstate Medical University

Bisphosphonate therapy is one of 50 small molecule programs targeting Childhood Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Childhood CancerActive, not recruiting

Postmenopausal OsteoporosisActive, not recruiting

Childhood CancerPreclinical

Active, not recruiting

Postmenopausal OsteoporosisApproved

Active, not recruiting

Competition

Competitive Landscape

53 competitors in Postmenopausal Osteoporosis

#DrugCompanyPhaseTrials

Zometa

Pfizer

Approved

3 2

Evista

Eli Lilly

Approved

2 3

Forteo

AAlmaject

Approved

8 4

Estrace

Novo Nordisk

Approved

—5

Calciferol

Alnylam Pharmaceuticals

Approved

—6

Boniva

CConrado Roberto Hoffmann Filho

Approved

2 7

Estradiol Valerate

Bayer

Approved

1 8

Xylocaine

MMEDRx USA, Inc.

Approved

—9

Versed

CConrado Roberto Hoffmann Filho

Approved

—10

Epsom Salt

FFresenius Kabi Oncology Ltd.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Postmenopausal Osteoporosis1 trial

Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis

Completed·OOndokuz Mayıs University·Phase 4·NCT04149405·43 enrolled

Childhood Cancer1 trial

Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density

Terminated·SState University of New York - Upstate Medical University·N/A·NCT00145704·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Bisphosphonate therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bisphosphonate therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bisphosphonate therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — State University of New York - Upstate Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SState University of New York - Upstate Medical University

Bisphosphonate therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Postmenopausal Osteoporosis1 trial

Childhood Cancer1 trial

References

Drug Info

Quick Facts

Related News